Glossary of Medication Monitoring
This Glossary highlights the recommended monitoring for certain IBD Medications as part of standard of
care. It is important that you review these recommendations with your GI Provider.
aminosalicylates –balsalazide, mesalamine
Apriso™
Asacol® HD
Colazal®
Giazo™
Canasa®
Delzicol™
Rowasa®
Lialda™
Pentasa®
Prior to Initiating Therapy
- Complete initial/baseline bloodwork such as complete blood counts, renal function, liver function
While on Therapy
- Complete yearly Renal (kidney) function test often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)
- Complete yearly urinalysis
aminosalicylates – sulfasalazine
Azulfidine®
Azulfidine® EN-tabs
Prior to Initiating Therapy
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
- Complete yearly urinalysis
- Take daily folic acid supplements (1mg /day and up 2 mg/day if pregnant)
NOTE: More frequent lab monitoring may be necessary during first few months of therapy
biologics – TNF-α (adalimumab, infliximab, certolizumab pegol, golimumab)
Humira®
Cyltezo™
Amjevita®
Hyrimoz™
Cimzia®
Simponi®
Remicade®
Renflexis®
Avsola
Inflectra™
IXIFI™
Prior to Initiating Therapy
- Complete Tuberculosis (TB) screening prior to initiating medication (e.g., QuantiFERON-TB Gold or PPD. If high risk or indeterminate results from QuantiFERON-TB Gold or PPD: Chest X-ray)
- Check Hepatitis B Immunity Status (preferably before starting therapy but can be done after starting therapy) and re/vaccinate if not immune
- Avoid live vaccines within 4 weeks of starting therapy and during therapy
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete annual TB risk assessment and screening if meeting criteria for high risk
- Avoid live vaccines
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
- Consider requesting a lab order to measure drug concentrations to ensure there is a therapeutic amount in your system, especially when you are symptomatic. (This can be considered shorty after starting therapy)
biologics – α4 integrin (natalizumab)
Tysabri®
Prior to Initiating Therapy
- Enroll in TOUCH program
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
biologics – IL-12/23 (ustekinumab)
IL-23 (risankizumαb)
Stelara®
Skyrizi®
Prior to Initiating Therapy
- Complete Tuberculosis (TB) screening prior to initiating medication (e.g., QuantiFERON-TB Gold or PPD. If high risk or indeterminate results from QuantiFERON-TB Gold or PPD: Chest X-ray)
- Avoid live vaccines within 4 weeks of starting therapy
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete annual TB risk assessment and screening if meeting criteria for high risk
- Avoid live vaccines
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months. For Skyrizi, liver function monitoring is recommended within the first 3 months of initiating therapy.
- Consider requesting a lab order to measure drug concentrations to ensure there is a therapeutic amount in your system, especially when you are symptomatic
biologics – α4β7 integrin (vedolizumab)
Entyvio®
Prior to Initiating Therapy
- Optional: Patients at high risk for tuberculosis (TB) may be screened for TB, at discretion of the provider
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
- Avoid live vaccines within 4 weeks of starting therapy
While on Therapy
- Avoid live vaccines
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
- Consider requesting a lab order to measure drug concentrations to ensure there is a therapeutic amount in your system, especially when you are symptomatic
corticosteroids – budesonide
Entocort® EC
Uceris™
- Daily Calcium of (1200-1500 mg) and Vitamin D supplements (1000-4000 IU daily or 50,000 Units weekly) is recommended
- Consider an ophthalmology exam to monitor for ocular side effects
- Inform your GI provider of all courses of steroids so a bone density exam* may be recommended, as necessary
Generally, a bone density exam may be considered if you have used oral corticosteroids lasting > 3 months, or if you have used oral corticosteroids lasting 1 year within the past 2 years.
Women 65 or older should receive a bone density for preventative screening every 2 years regardless of steroid exposure.
corticosteroids – prednisone
A-Methapred®
Depo-Medrol®
Medrol Dosepak®
Solu-Medrol®
Deltasone®
Oraped®
Prelone®
Pediapred®
- Daily Calcium of (1200-1500 mg) and Vitamin D supplements (1000-4000 IU daily or 50,000 Units weekly) is recommended
- Consider an ophthalmology exam to monitor for ocular side effects
- Inform your GI provider of all courses of steroids so a bone density exam* may be recommended, as necessary
Generally, a bone density exam may be considered if you have used oral corticosteroids lasting > 3 months, or if you have used oral corticosteroids lasting 1 year within the past 2 years.
Women 65 or older should receive a bone density for preventative screening every 2 years regardless of steroid exposure.
immunosuppressant – cyclosporine
Neoral®
Sandimmune®
Gengraf®
Prior to Initiating Therapy
- Review all medications, including herbal supplements, with provider
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function, potassium levels [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)], cholesterol, and magnesium levels
While on Therapy
- Avoid grapefruit juice
- Complete routine monitoring of drug concentrations and bloodwork such as complete blood count, renal function, liver function, potassium levels [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)], cholesterol and magnesium levels every 3-6 months
- Ensure consistency of taking medication, either always with food or always without food
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider
immunosuppressant – methotrexate
Rheumatrex®
MTX®
Mexate®
Trexall®
Prior to Initiating Therapy
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
- Take daily folic acid supplements (1 mg/day)
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider
immunosuppressant – tacrolimus
Prograf®
Astagraf XL®
Envarsus® XR
Hecoria®
Prior to Initiating Therapy
- Review all medications, including herbal supplements, with provider
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function, potassium levels [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)], cholesterol, and magnesium levels
While on Therapy
- Avoid grapefruit juice
- Ensure consistency of taking medication, either always with food or always without food
- Complete routine monitoring of drug concentrations and bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)], cholesterol, and magnesium levels every 3-6 months
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider
immunosuppressant – thiopurine, azathioprine, 6-Mercaptopurine (6-MP)
Imuran®
Azasan®
Purinethol®
Purixan
Prior to Initiating Therapy
- Complete Thiopurine methyltransferase (TPMT) enzyme blood test to ensure a safe start to the medication. Results can impact starting dose.
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
- Consider requesting a lab order to measure drug concentrations to ensure there is a therapeutic amount in your system (Thiopurine Metabolites)
NOTE: White blood cell counts should be monitored more often in the first 3 months of therapy
small molecules – JAK-inhibitor (tofacitinib, upadacitinib)
Xeljanz®
Rinvoq®
Prior to Initiating Therapy
- Complete Tuberculosis (TB) screening prior to initiating medication (e.g., QuantiFERON-TB Gold or PPD. If high risk or indeterminate results from QuantiFERON-TB Gold or PPD: Chest X-ray)
- Avoid live vaccines within 4 weeks of starting therapy and during therapy
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
- Consider the Inactive Herpes Zoster vaccine (Shingrix) especially if you are above the age of 50. Please discuss with your GI provider and primary care provider.
While on Therapy
- Complete a Fasting Lipid Profile, recommended 4-8 weeks after starting therapy
- Complete annual TB risk assessment and screening if you meet criteria for high risk
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider
small molecules – S1P Receptor Molecules (ozanimod)
Zeposia®
Prior to Initiating Therapy
- Complete an Electrocardiogram (EKG) to screen for preexisting conduction abnormalities
- Complete blood pressure monitoring
- Review all your medications with your provider to ensure they don’t impact your heart rate
- Visit an ophthalmologist if you have diabetes or if you are diagnosed with inflammation or swelling inside your eye
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
- Consider the Inactive Herpes Zoster vaccine (Shingrix), especially if above the age of 50. Please discuss with your GI provider and primary care provider
While on Therapy
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
Initial Dosing Schedule
Days 1-4 | 0.23 mg per day |
Days 5-7 | 0.46 mg per day |
After Day 7 | 0.92 mg (Full Dose) per day |
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider
IBD Medication
aminosalicylates –balsalazide, mesalamine
Common Brands
Apriso™
Asacol® HD
Colazal®
Giazo™
Canasa®
Delzicol™
Rowasa®
Lialda™
Pentasa®
Recommended Safety Checks
Prior to Initiating Therapy
- Complete initial/baseline bloodwork such as complete blood counts, renal function, liver function
While on Therapy
- Complete yearly Renal (kidney) function test often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)
- Complete yearly urinalysis
IBD Medication
aminosalicylates – sulfasalazine
Common Brands
Azulfidine®
Azulfidine® EN-tabs
Recommended Safety Checks
Prior to Initiating Therapy
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
- Complete yearly urinalysis
- Take daily folic acid supplements (1mg /day and up 2 mg/day if pregnant)
NOTE: More frequent lab monitoring may be necessary during first few months of therapy
IBD Medication
biologics – TNF-α (adalimumab, infliximab, certolizumab pegol, golimumab)
Common Brands
Humira®
Cyltezo™
Amjevita®
Hyrimoz™
Cimzia®
Simponi®
Remicade®
Renflexis®
Avsola
Inflectra™
IXIFI™
Recommended Safety Checks
Prior to Initiating Therapy
- Complete Tuberculosis (TB) screening prior to initiating medication (e.g., QuantiFERON-TB Gold or PPD. If high risk or indeterminate results from QuantiFERON-TB Gold or PPD: Chest X-ray)
- Check Hepatitis B Immunity Status (preferably before starting therapy but can be done after starting therapy) and re/vaccinate if not immune
- Avoid live vaccines within 4 weeks of starting therapy and during therapy
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete annual TB risk assessment and screening if meeting criteria for high risk
- Avoid live vaccines
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
- Consider requesting a lab order to measure drug concentrations to ensure there is a therapeutic amount in your system, especially when you are symptomatic. (This can be considered shorty after starting therapy)
IBD Medication
biologics – α4 integrin (natalizumab)
Common Brands
Tysabri®
Recommended Safety Checks
Prior to Initiating Therapy
- Enroll in TOUCH program
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
IBD Medication
biologics – IL-12/23 (ustekinumab)
IL-23 (risankizumαb)
Common Brands
Stelara®
Skyrizi®
Recommended Safety Checks
Prior to Initiating Therapy
- Complete Tuberculosis (TB) screening prior to initiating medication (e.g., QuantiFERON-TB Gold or PPD. If high risk or indeterminate results from QuantiFERON-TB Gold or PPD: Chest X-ray)
- Avoid live vaccines within 4 weeks of starting therapy
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete annual TB risk assessment and screening if meeting criteria for high risk
- Avoid live vaccines
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months. For Skyrizi, liver function monitoring is recommended within the first 3 months of initiating therapy.
- Consider requesting a lab order to measure drug concentrations to ensure there is a therapeutic amount in your system, especially when you are symptomatic
IBD Medication
biologics – α4β7 integrin (vedolizumab)
Common Brands
Entyvio®
Recommended Safety Checks
Prior to Initiating Therapy
- Optional: Patients at high risk for tuberculosis (TB) may be screened for TB, at discretion of the provider
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
- Avoid live vaccines within 4 weeks of starting therapy
While on Therapy
- Avoid live vaccines
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
- Consider requesting a lab order to measure drug concentrations to ensure there is a therapeutic amount in your system, especially when you are symptomatic
IBD Medication
corticosteroids – budesonide
Common Brands
Entocort® EC
Uceris™
Recommended Safety Checks
- Daily Calcium of (1200-1500 mg) and Vitamin D supplements (1000-4000 IU daily or 50,000 Units weekly) is recommended
- Consider an ophthalmology exam to monitor for ocular side effects
- Inform your GI provider of all courses of steroids so a bone density exam* may be recommended, as necessary
Generally, a bone density exam may be considered if you have used oral corticosteroids lasting > 3 months, or if you have used oral corticosteroids lasting 1 year within the past 2 years.
Women 65 or older should receive a bone density for preventative screening every 2 years regardless of steroid exposure.
IBD Medication
corticosteroids – prednisone
Common Brands
A-Methapred®
Depo-Medrol®
Medrol Dosepak®
Solu-Medrol®
Deltasone®
Oraped®
Prelone®
Pediapred®
Recommended Safety Checks
- Daily Calcium of (1200-1500 mg) and Vitamin D supplements (1000-4000 IU daily or 50,000 Units weekly) is recommended
- Consider an ophthalmology exam to monitor for ocular side effects
- Inform your GI provider of all courses of steroids so a bone density exam* may be recommended, as necessary
Generally, a bone density exam may be considered if you have used oral corticosteroids lasting > 3 months, or if you have used oral corticosteroids lasting 1 year within the past 2 years.
Women 65 or older should receive a bone density for preventative screening every 2 years regardless of steroid exposure.
IBD Medication
immunosuppressant – cyclosporine
Common Brands
Neoral®
Sandimmune®
Gengraf®
Recommended Safety Checks
Prior to Initiating Therapy
- Review all medications, including herbal supplements, with provider
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function, potassium levels [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)], cholesterol, and magnesium levels
While on Therapy
- Avoid grapefruit juice
- Complete routine monitoring of drug concentrations and bloodwork such as complete blood count, renal function, liver function, potassium levels [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)], cholesterol and magnesium levels every 3-6 months
- Ensure consistency of taking medication, either always with food or always without food
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider
IBD Medication
immunosuppressant – methotrexate
Common Brands
Rheumatrex®
MTX®
Mexate®
Trexall®
Recommended Safety Checks
Prior to Initiating Therapy
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
- Take daily folic acid supplements (1 mg/day)
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider
IBD Medication
immunosuppressant – tacrolimus
Common Brands
Prograf®
Astagraf XL®
Envarsus® XR
Hecoria®
Recommended Safety Checks
Prior to Initiating Therapy
- Review all medications, including herbal supplements, with provider
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function, potassium levels [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)], cholesterol, and magnesium levels
While on Therapy
- Avoid grapefruit juice
- Ensure consistency of taking medication, either always with food or always without food
- Complete routine monitoring of drug concentrations and bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)], cholesterol, and magnesium levels every 3-6 months
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider
IBD Medication
immunosuppressant – thiopurine, azathioprine, 6-Mercaptopurine (6-MP)
Common Brands
Imuran®
Azasan®
Purinethol®
Purixan
Recommended Safety Checks
Prior to Initiating Therapy
- Complete Thiopurine methyltransferase (TPMT) enzyme blood test to ensure a safe start to the medication. Results can impact starting dose.
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
While on Therapy
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
- Consider requesting a lab order to measure drug concentrations to ensure there is a therapeutic amount in your system (Thiopurine Metabolites)
NOTE: White blood cell counts should be monitored more often in the first 3 months of therapy
IBD Medication
small molecules – JAK-inhibitor (tofacitinib, upadacitinib)
Common Brands
Xeljanz®
Rinvoq®
Recommended Safety Checks
Prior to Initiating Therapy
- Complete Tuberculosis (TB) screening prior to initiating medication (e.g., QuantiFERON-TB Gold or PPD. If high risk or indeterminate results from QuantiFERON-TB Gold or PPD: Chest X-ray)
- Avoid live vaccines within 4 weeks of starting therapy and during therapy
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
- Consider the Inactive Herpes Zoster vaccine (Shingrix) especially if you are above the age of 50. Please discuss with your GI provider and primary care provider.
While on Therapy
- Complete a Fasting Lipid Profile, recommended 4-8 weeks after starting therapy
- Complete annual TB risk assessment and screening if you meet criteria for high risk
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider
IBD Medication
small molecules – S1P Receptor Molecules (ozanimod)
Common Brands
Zeposia®
Recommended Safety Checks
Prior to Initiating Therapy
- Complete an Electrocardiogram (EKG) to screen for preexisting conduction abnormalities
- Complete blood pressure monitoring
- Review all your medications with your provider to ensure they don’t impact your heart rate
- Visit an ophthalmologist if you have diabetes or if you are diagnosed with inflammation or swelling inside your eye
- Complete initial/baseline bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)]
- Consider the Inactive Herpes Zoster vaccine (Shingrix), especially if above the age of 50. Please discuss with your GI provider and primary care provider
While on Therapy
- Complete routine bloodwork such as complete blood count, renal function, liver function [often part of a Basic or Comprehensive Metabolic Panel (BMP/CMP)] every 3-6 months
Initial Dosing Schedule
Days 1-4 | 0.23 mg per day |
Days 5-7 | 0.46 mg per day |
After Day 7 | 0.92 mg (Full Dose) per day |
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider
IBD Medication | Common Brands | Recommended Safety Checks | ||||||
---|---|---|---|---|---|---|---|---|
aminosalicylates –balsalazide, mesalamine |
Apriso™ Asacol® HD Colazal® Giazo™ Canasa® Delzicol™ Rowasa® Lialda™ Pentasa® |
Prior to Initiating Therapy
While on Therapy
|
||||||
aminosalicylates – sulfasalazine |
Azulfidine® Azulfidine® EN-tabs |
Prior to Initiating Therapy
While on Therapy
NOTE: More frequent lab monitoring may be necessary during first few months of therapy |
||||||
biologics – TNF-α (adalimumab, infliximab, certolizumab pegol, golimumab) |
Humira® Cyltezo™ Amjevita® Hyrimoz™ Cimzia® Simponi® Remicade® Renflexis® Avsola Inflectra™ IXIFI™ |
Prior to Initiating Therapy
While on Therapy
Traveling Soon? You may be considered high-risk for TB if you are traveling to certain countries. Check if your destination is high-risk for TB here: https://wwwnc.cdc.gov/travel/destinations/list
|
||||||
biologics – α4 integrin (natalizumab) |
Tysabri® |
Prior to Initiating Therapy
While on Therapy
|
||||||
biologics – IL-12/23 (ustekinumab) IL-23 (risankizumαb) |
Stelara® Skyrizi® |
Prior to Initiating Therapy
While on Therapy
Traveling Soon? You may be considered high-risk for TB if you are traveling to certain countries. Check if your destination is high-risk for TB here: https://wwwnc.cdc.gov/travel/destinations/list
|
||||||
biologics – α4β7 integrin (vedolizumab) |
Entyvio® |
Prior to Initiating Therapy
While on Therapy
|
||||||
corticosteroids – budesonide |
Entocort® EC Uceris™ |
Generally, a bone density exam may be considered if you have used oral corticosteroids lasting > 3 months, or if you have used oral corticosteroids lasting 1 year within the past 2 years. Women 65 or older should receive a bone density for preventative screening every 2 years regardless of steroid exposure. |
||||||
corticosteroids – prednisone |
A-Methapred® |
Generally, a bone density exam may be considered if you have used oral corticosteroids lasting > 3 months, or if you have used oral corticosteroids lasting 1 year within the past 2 years. Women 65 or older should receive a bone density for preventative screening every 2 years regardless of steroid exposure. |
||||||
immunosuppressant – cyclosporine |
Neoral® Sandimmune® Gengraf® |
Prior to Initiating Therapy
While on Therapy
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider |
||||||
immunosuppressant – methotrexate |
Rheumatrex® MTX® Mexate® Trexall® |
Prior to Initiating Therapy
While on Therapy
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider Considering Pregnancy? It is recommended to stop this therapy 3-6 months prior to getting pregnant. Please include your GI provider in discussions when family-planning so they can support you in having a healthy pregnancy while keeping your IBD under control.
|
||||||
immunosuppressant – tacrolimus |
Prograf® Astagraf XL® Envarsus® XR Hecoria® |
Prior to Initiating Therapy
While on Therapy
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider |
||||||
immunosuppressant – thiopurine, azathioprine, 6-Mercaptopurine (6-MP) |
Imuran® Azasan® Purinethol® Purixan |
Prior to Initiating Therapy
While on Therapy
NOTE: White blood cell counts should be monitored more often in the first 3 months of therapy |
||||||
small molecules – JAK-inhibitor (tofacitinib, upadacitinib) |
Xeljanz® Rinvoq® |
Prior to Initiating Therapy
While on Therapy
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider Traveling Soon? You may be considered high-risk for TB if you are traveling to certain countries. Check if your destination is high-risk for TB here: https://wwwnc.cdc.gov/travel/destinations/list
Considering Pregnancy? Your GI provider may need to adjust your IBD care plan, so please include your GI provider in discussions when family-planning
|
||||||
small molecules – S1P Receptor Molecules (ozanimod) |
Zeposia® |
Prior to Initiating Therapy
While on Therapy
Initial Dosing Schedule
NOTE: Bloodwork should be monitored more often in the first 3 months of therapy and should be discussed with your provider Considering Pregnancy? It is recommended to stop this therapy 3-6 months prior to getting pregnant. Please include your GI provider in discussions when family-planning so they can support you in having a healthy pregnancy while keeping your IBD under control.
|